Bil­lion­aire Bertarel­li's Way­point steers al­ler­gy drug­mak­er Stal­ler­genes Greer pri­vate in $832M buy­out deal

The flur­ry of 2019 M&A ac­tiv­i­ty is show­ing no signs of cool­ing. Al­ler­gy im­munother­a­py mak­er Stal­ler­genes Greer has agreed to be ac­quired by the Way­point/Ares Life Sci­ences ve­hi­cle of Swiss bil­lion­aire and for­mer Serono chief Ernesto Bertarel­li for €730.1 mil­lion (about $832 mil­lion) in a deal de­vised to take the French com­pa­ny pri­vate.

Way­point has been the biggest share­hold­er of Stal­ler­genes since it was es­tab­lished in 2015, and cur­rent­ly holds a 83.9% stake.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER